CE Mark for NEXT WAVE Brain Stimulation Device

EBS Technologies GmbH, developer of the NEXT WAVE brain stimulation platform for treatment of neurological disorders caused by stroke and brain injury, received CE marking for NEXT WAVE. Officials from the company expect to begin commercialization in Europe immediately as the result of closing a Series “B” financing round of $3.9 million (€3,0 million) from existing investors: including lead investor Earlybird Venture Partners, High-Tech Gründerfonds (HTGF), and Brandenburg Capital. Total investment in EBS Technologies is $8.7 million (€6,7 million).

“There is a very significant unmet clinical need for the treatment of vision impairment caused by a neurological disorder such as a stroke,” states Ulf Pommerening, CEO of EBS Technologies. “For example, stroke is the world’s third-leading cause of death as well as the leading cause of serious, long-term disability. There are more than 10 million stroke survivors with long-term disability in Europe and the U.S. Three out of five of these disabled persons are potentially treatable with our non-invasive EBS Next Wave therapy.

“We are extremely pleased that our existing investors, led by Earlybird Venture Partners, increased their commitment to EBS, based on strong clinical results with our low-risk, non-invasive NEXT WAVE system,” Pommerening adds. “With this Series B cash infusion, we have already begun a limited launch of the device to key opinion-leading neurologists in Europe.”

About Next Wave
The NEXT WAVE technology enables a unique revitalization of selective communication paths between neurological cells, which may have been lost due to brain injury caused by trauma, stroke, or tumor resection. The non-invasive therapy utilizing the patented NEXT WAVE technology is clinically validated to restore vision impairment by 20% to 30% after brain dysfunction. In addition, glaucoma patients have shown to benefit from the NEXT WAVE technology.

NOTE: NEXT WAVE is approved for sale in Europe; it is not approved for sale or investigational use in the U.S.